Maximum Tolerated Dose
"Maximum Tolerated Dose" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
Descriptor ID |
D020714
|
MeSH Number(s) |
E05.940.481 G07.690.570
|
Concept/Terms |
Maximum Tolerated Dose- Maximum Tolerated Dose
- Dose, Maximum Tolerated
- Doses, Maximum Tolerated
- Maximum Tolerated Doses
- Tolerated Dose, Maximum
- Tolerated Doses, Maximum
- Maximal Tolerated Dose
- Dose, Maximal Tolerated
- Doses, Maximal Tolerated
- Maximal Tolerated Doses
- Tolerated Dose, Maximal
- Tolerated Doses, Maximal
- Maximally Tolerated Dose
- Dose, Maximally Tolerated
- Doses, Maximally Tolerated
- Maximally Tolerated Doses
- Tolerated Dose, Maximally
- Tolerated Doses, Maximally
|
Below are MeSH descriptors whose meaning is more general than "Maximum Tolerated Dose".
Below are MeSH descriptors whose meaning is more specific than "Maximum Tolerated Dose".
This graph shows the total number of publications written about "Maximum Tolerated Dose" by people in UAMS Profiles by year, and whether "Maximum Tolerated Dose" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2022 | 0 | 1 | 1 | 2021 | 0 | 2 | 2 | 2019 | 0 | 3 | 3 | 2018 | 0 | 1 | 1 | 2017 | 0 | 2 | 2 | 2014 | 0 | 2 | 2 | 2010 | 0 | 3 | 3 | 2009 | 0 | 3 | 3 | 2008 | 0 | 1 | 1 | 2007 | 0 | 2 | 2 | 2006 | 0 | 1 | 1 | 2004 | 0 | 3 | 3 | 2003 | 1 | 1 | 2 | 2002 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Maximum Tolerated Dose" by people in Profiles over the past ten years.
-
Saulnier-Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L, Jain RK. A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clin Cancer Res. 2022 09 15; 28(18):3950-3957.
-
Wu J, Yuan Y, Long Priel DA, Fink D, Peer CJ, Sissung TM, Su YT, Pang Y, Yu G, Butler MK, Mendoza TR, Vera E, Ahmad S, Bryla C, Lindsley M, Grajkowska E, Mentges K, Boris L, Antony R, Garren N, Siegel C, Lollo N, Cordova C, Aboud O, Theeler BJ, Burton EM, Penas-Prado M, Leeper H, Gonzales J, Armstrong TS, Calvo KR, Figg WD, Kuhns DB, Gallin JI, Gilbert MR. Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clin Cancer Res. 2021 06 15; 27(12):3298-3306.
-
Mascarenhas L, Ogawa C, Laetsch TW, Weigel BJ, Bishop MW, Krystal J, Borinstein SC, Slotkin EK, Muscal JA, Hingorani P, Levy DE, Mo G, Shahir A, Wright J, DuBois SG. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Med. 2021 02; 10(3):843-856.
-
Culp WC, Onteddu SS, Brown A, Nalleballe K, Sharma R, Skinner RD, Witt T, Roberson PK, Marsh JD. Dodecafluoropentane Emulsion in Acute Ischemic Stroke: A Phase Ib/II Randomized and Controlled Dose-Escalation Trial. J Vasc Interv Radiol. 2019 Aug; 30(8):1244-1250.e1.
-
Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580.
-
Mikhael J, Richardson P, Usmani SZ, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, Semiond D, Anderson K. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019 07 11; 134(2):123-133.
-
Taylor SE, Petschauer JS, Donovan H, Schorzman A, Razo J, Zamboni WC, Edwards RP, Zorn KK. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer. Int J Gynecol Cancer. 2019 01; 29(1):147-152.
-
Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
-
Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo M, Rabin N, Kurman M, Novak B, Shiraishi N, Nakashima D, Akinaga S, Yong K. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Br J Cancer. 2017 Oct 24; 117(9):1295-1302.
-
Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087.
-
Marrero L, Wyczechowska D, Musto AE, Wilk A, Vashistha H, Zapata A, Walker C, Velasco-Gonzalez C, Parsons C, Wieland S, Levitt D, Reiss K, Prakash O. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma. Neoplasia. 2014 Oct; 16(10):874-82.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|